TP73 and central nervous system cancer: TP73-AS1 was initially described in a study on oligodendroglial tumors, which revealed that TP73-AS1 was downregulated in tumor samples mainly via epigenetic modifications and chromosome 1p loss, and the knockdown of TP73-AS1 induced cisplatin resistance in glioma cells31.